AVI-7288 FOR MARBURG
We are developing AVI-7288 for the treatment of Marburg virus infection under a contract with the U.S. Department of Defense managed by the Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.
- PHASE 1
- PHASE 2
- PHASE 3
- AVI-7288MARBURG VIRUS
- AVI-7537EBOLA VIRUS
- VIRAL PMO-XDENGUE
- BACTERIAL PPMOTB
- UNDISCLOSED TARGET
RECENT PRESS RELEASES
Marburg hemorrhagic fever is a severe and often fatal disease endemic to Africa. Marburg is classified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention, and has been designated as a material threat to national security and public health by the U.S. Department of Homeland Security.
AVI-7288 is designed to bind to viral RNA and inhibit the synthesis of the nucleocapsid protein (NP). NP supports the replication of the viral genetic material in an infected cell, and is also involved in the assembly of mature viruses. Inhibition of NP is intended to interrupt the viral lifecycle and stop or slow the spread of the disease to other cells in the body.
AVI-7288 is based on our proprietary next-generation PMOplus® chemistry, which is also used across our infectious disease pipeline, including our lead investigational candidate for influenza.
Clinical development of AVI-7288 is being conducted pursuant to the U.S. Food and Drug Administration’s Animal Efficacy Rule, which is designed to facilitate the development of new drug products for indications in which conducting controlled clinical trials to determine efficacy in humans may be unethical or unfeasible. According to this rule, marketing approval may be granted based on the demonstration of efficacy in relevant animal species and safety in healthy human subjects.